You just read:

Phase 1/2 Clinical Trial of Apexigen's APX005M in Combination with Pembrolizumab (Keytruda®) Opens for Metastatic Melanoma Patients

News provided by

Apexigen, Inc.

21 Mar, 2017, 07:00 ET